Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 55

Results For "Center"

1145 News Found

Syntegon showcases oral solid dosage portfolio at Achema
News | April 11, 2024

Syntegon showcases oral solid dosage portfolio at Achema

Fluid bed processes: drying, granulating, and coating in just one product container


Lupin launches first generic version of Oracea in US
News | April 10, 2024

Lupin launches first generic version of Oracea in US

Doxycycline Capsules, 40 mg is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients


Wacker and Pantherna intensify collaboration in the development and production of mRNA biopharmaceuticals
Biotech | April 07, 2024

Wacker and Pantherna intensify collaboration in the development and production of mRNA biopharmaceuticals

Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry


Enhertu approved in the US as first tumour-agnostic HER2-directed therapy
Drug Approval | April 06, 2024

Enhertu approved in the US as first tumour-agnostic HER2-directed therapy

Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers


Imfinzi significantly improved overall survival and progression-free survival in ADRIATIC Phase III trial
Clinical Trials | April 06, 2024

Imfinzi significantly improved overall survival and progression-free survival in ADRIATIC Phase III trial

First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial


Merck initiates Phase 3 clinical trial of investigational oral KRAS G12C inhibitor MK-1084
Clinical Trials | April 05, 2024

Merck initiates Phase 3 clinical trial of investigational oral KRAS G12C inhibitor MK-1084

For the first-line treatment of certain patients with metastatic non-small cell lung cancer


Abbott receives FDA approval for TriClip
Drug Approval | April 04, 2024

Abbott receives FDA approval for TriClip

TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery


EC expands Reblozyl’s approval for treatment of myelodysplastic syndromes
Drug Approval | April 03, 2024

EC expands Reblozyl’s approval for treatment of myelodysplastic syndromes

This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia


Truqap plus Faslodex approved in Japan for patients with advanced HR-positive breast cancer
Drug Approval | March 30, 2024

Truqap plus Faslodex approved in Japan for patients with advanced HR-positive breast cancer

First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations


NMPA accepts supplemental Biologics License Application for enfortumab vedotin with Keytruda for treatment of bladder cancer
Drug Approval | March 30, 2024

NMPA accepts supplemental Biologics License Application for enfortumab vedotin with Keytruda for treatment of bladder cancer

If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy